Pretzel Therapeutics Inc. has described DNA polymerase subunit γ-1 (POLG) modulators reported to be useful for the treatment of neurodegeneration and mitochondrial diseases.
Researchers from Pretzel Therapeutics Inc. and the University of Gothenburg have published new insights on how mutations in the POLG gene affect its functionality and are tied to PolG diseases. They have also presented a compound for its potential treatment, PZL-A. They published their results in Nature on April 9, 2025.
Pretzel Therapeutics Inc. has disclosed DNA polymerase subunit γ-1 (POLG) modulators reported to be useful for the treatment of neurodegeneration and mitochondrial diseases.
Pretzel Therapeutics Inc. has patented heterocycle-containing compounds acting as Lon protease homolog, mitochondrial (LONP1) inhibitors. They are reported to be useful for the treatment of cancer, aging, neurodegeneration and metabolic diseases.
Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
